(3 months, 1 week ago)
Commons ChamberI am sure I speak for the whole House when I join my hon. Friend in sending our condolences to the family and friends of her predecessor.
Our employment relation teams are working hard with local employers to match customers to the vacancies in my hon. Friend’s businesses. We are building skills, working with sector-based work academy programmes and boot camps, supporting people with a generous increased childcare offer of up to £1,000 for one child and £1,700 for two, and helping people with access to travel. For those on the health journey, later this year we will roll out our WorkWell programme across England, including in areas in the south-west.
On specific days, jobcentres have been closed due to ongoing industrial action. Can the Minister assure me that anybody who misses an appointment due to that action will not be sanctioned?
We will always take a reasonable view and make sure that unavoidable circumstances such as those the hon. Gentleman speaks of will be taken into account when talking to customers.
(3 years, 2 months ago)
Commons ChamberI have discussed these concerns with the hon. Member and with the co-chairs of the all-party parliamentary group on medical cannabis under prescription, and he knows that I sympathise deeply with the parents of these children and with the patients and their families, many of whom I have met. They are dealing courageously with conditions that are difficult to treat. My immediate priority was to resolve the supply of Bedrocan oil from the Netherlands. I have further meetings planned to make progress on other issues in this incredibly complex situation.
I welcome today’s letter from the Minister detailing the extension of the arrangements for the provision of Bedrocan, and I am pleased that we are working towards the manufacture of Bedrocan oils in the UK. I have two issues today. The first is that patients still need to pay for their medicines. If the numbers are so small and this is such a niche product, surely it could be provided free on the NHS. Secondly, I have been told that research is ongoing regarding the wider possibilities for medical cannabis, but despite being promised an update a month ago, I am still waiting for one from the Medicines and Healthcare Products Regulatory Agency on clinical trials and the licence application. Could that please be forthcoming?
As the hon. Gentleman knows, I have met Dr June Raine from the MHRA and subsequently met further specialist clinicians in this area to discuss progress with the research and evidence on supporting prescribing on the NHS. Establishing clinical trials is vital, with the support of the National Institute for Health Research, to make sure that we are making the right decisions on routine funding. From 1 April, we have introduced a national patient registry to record data and monitor patient outcomes in England, with a view to it being rolled out across Scotland and the other devolved Administrations later this year; this covers both licensed and unlicensed cannabis-based medicines on the NHS, with a view to including private patients in due course. As he knows, I am very focused on making sure we get the right solutions for families, but at the heart of this matter always has to lie the safety of what we prescribe.